Press Release: Sanofiās amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
(NASDAQ:SNY) Sanofiās amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Related Questions
How will the COAST 1 results affect Sanofiās upcoming earnings guidance and shortāterm stock performance?
What is the expected timeline for FDA approval of amlitelimab and how might it compete with existing biologics for atopic dermatitis like dupixent?
What impact could the launch of amlitelimab have on Sanofiās broader dermatology pipeline and longāterm market positioning?